CD4 antibody [RPA-T4] (FITC)
GTX74817
ApplicationsFlow Cytometry
Product group Antibodies
ReactivityHuman
TargetCD4
Overview
- SupplierGeneTex
- Product NameCD4 antibody [RPA-T4] (FITC)
- Delivery Days Customer9
- Application Supplier NoteFACS: 1 microg (5 microl) for 105-108 cells in 100 microl sample per test. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsFlow Cytometry
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDRPA-T4
- Concentration0.2 mg/ml
- ConjugateFITC
- Gene ID920
- Target nameCD4
- Target descriptionCD4 molecule
- Target synonymsCD4mut, IMD79, Leu-3, OKT4D, T4, T-cell surface glycoprotein CD4, CD4 antigen (p55), CD4 receptor, T-cell surface antigen T4/Leu-3
- HostMouse
- IsotypeIgG1
- Protein IDP01730
- Protein NameT-cell surface glycoprotein CD4
- Scientific DescriptionThis gene encodes a membrane glycoprotein of T lymphocytes that interacts with major histocompatibility complex class II antigenes and is also a receptor for the human immunodeficiency virus. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, and granulocytes. It is also expressed in specific regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene. [provided by RefSeq, Aug 2010]
- ReactivityHuman
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014,20(10):1126-9. doi: 10.1038/nm.3702Read this paper
- Toma J, Weinheimer SP, Stawiski E, et al. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol. 2011,85(8):3872-80. doi: 10.1128/JVI.02237-10Read this paper
- Porter KA, Kelley LN, Nekorchuk MD, et al. CIITA enhances HIV-1 attachment to CD4+ T cells leading to enhanced infection and cell depletion. J Immunol. 2010,185(11):6480-8. doi: 10.4049/jimmunol.1000830Read this paper
- Hsieh SC, Tsai WY, Wang WK. The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum. J Virol. 2010,84(9):4782-97. doi: 10.1128/JVI.01963-09Read this paper
- Decker JM, Zammit KP, Easlick JL, et al. Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes. Virology. 2009,394(1):109-18. doi: 10.1016/j.virol.2009.08.027Read this paper
- Chen X, Wang X, Besra GS, et al. Modulation of CD1d-restricted NKT cell responses by CD4. J Leukoc Biol. 2007,82(6):1455-65.Read this paper
- Thedrez A, de Lalla C, Allain S, et al. CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood. 2007,110(1):251-8.Read this paper
- Deng MC, Bell S, Huie P, et al. Cardiac allograft vascular disease. Relationship to microvascular cell surface markers and inflammatory cell phenotypes on endomyocardial biopsy. Circulation. 1995,91(6):1647-54.Read this paper






